SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from Traws Pharma, Inc. (TRAW) (CIK 0001130598) (TRAW) — Apr 26, 2018

Traws Pharma, Inc. (TRAW) (CIK 0001130598)
Date: April 26, 2018 · CIK: 0001130598 · Accession: 0001104659-18-027189

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-224315

Date
April 26, 2018
Author
Edward D. Silvera
Form
CORRESP
Company
Traws Pharma, Inc. (TRAW) (CIK 0001130598)

Letter

Re: Onconova Therapeutics, Inc.

April 26, 2018

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F. Street, N.E.

Washington, DC 20549

Registration Statement on Form S-1 (File No. 333-224315)

Concurrence in Acceleration Request

Ladies and Gentlemen:

H.C. Wainwright & Co., LLC (“Wainwright”), as underwriter for the referenced offering, hereby concurs in the request by Onconova Therapeutics, Inc. that the effective date of the above-referenced registration statement be accelerated to 4:30 P.M. (Eastern Time), or as soon as practicable thereafter, on April 26, 2018, pursuant to Rule 461 under the Securities Act. Wainwright affirms that it is aware of its obligations under the Securities Act in connection with this offering.

H.C. WAINWRIGHT & CO., LLC

By:

/s/ Edward D. Silvera

Name:

Edward D. Silvera

Title:

Chief Operating Officer

430 Park Avenue | New York, New York 10022 | 212.356.0500

Security services provided by H.C. Wainwright & Co., LLC | Member: FINRA/SIPC

Show Raw Text
CORRESP
1
filename1.htm

April 26, 2018

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F. Street, N.E.

Washington, DC 20549

Re:    Onconova Therapeutics, Inc.

Registration Statement on Form S-1 (File No. 333-224315)

Concurrence in Acceleration Request

Ladies and Gentlemen:

H.C. Wainwright & Co., LLC (“Wainwright”), as underwriter for the referenced offering, hereby concurs in the request by Onconova Therapeutics, Inc. that the effective date of the above-referenced registration statement be accelerated to 4:30 P.M. (Eastern Time), or as soon as practicable thereafter, on April 26, 2018, pursuant to Rule 461 under the Securities Act. Wainwright affirms that it is aware of its obligations under the Securities Act in connection with this offering.

H.C. WAINWRIGHT & CO., LLC

By:

/s/   Edward D. Silvera

Name:

Edward   D. Silvera

Title:

Chief   Operating Officer

430 Park Avenue | New York, New York 10022 | 212.356.0500

Security services provided by H.C. Wainwright & Co., LLC | Member: FINRA/SIPC